Brett P Monia sold $12M of IONS
Chief Executive Officer at IONIS PHARMACEUTICALS INC. 160,773 shares at an average of $75.35, traded Mar 9, 2026, filed Mar 11, 2026.
Score components
- +25RoleCEO
- +25Trade size$12.1M at market
- +10Share of holdings soldSold 44% of holdings
- +15Cluster11 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +0.5%, 3m -2.0%, 6m -25.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000874015-26-000143, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | MOption exercise Common Stock10b5-1 | +40,822 | $60.89 | $2.5M | 295,803 | Mar 11, 2026 |
| Mar 9, 2026 | MOption exercise Common Stock10b5-1 | +73,529 | $60.89 | $4.5M | 369,332 | Mar 11, 2026 |
| Mar 9, 2026 | SOpen-market sale Common Stock10b5-1 | -7,382 | $74.11 | $547k | 361,950 | Mar 11, 2026 |
| Mar 9, 2026 | SOpen-market sale Common Stock10b5-1 | -117,604 | $75.26 | $8.9M | 244,346 | Mar 11, 2026 |
| Mar 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1,684 | $75.58 | $127k | 242,662 | Mar 11, 2026 |
| Mar 10, 2026 | MOption exercise Common Stock10b5-1 | +34,103 | $60.89 | $2.1M | 276,765 | Mar 11, 2026 |
| Mar 10, 2026 | SOpen-market sale Common Stock10b5-1 | -16,512 | $75.47 | $1.2M | 260,253 | Mar 11, 2026 |
| Mar 10, 2026 | SOpen-market sale Common Stock10b5-1 | -17,591 | $76.34 | $1.3M | 242,662 | Mar 11, 2026 |
| Mar 9, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -40,822 | $0.00 | $0 | 107,632 | Mar 11, 2026 |
| Mar 9, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -73,529 | $0.00 | $0 | 34,103 | Mar 11, 2026 |
| Mar 10, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -34,103 | $0.00 | $0 | 0 | Mar 11, 2026 |
Related signals
Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 58Moderate | IONSbuy IONIS PHARMACEUTICALS INC | Michael R Hayden director | $1.1M 20,000 shares | +500% | |
| 45Moderate | IONIS PHARMACEUTICALS INC | C Frank Bennett EVP, Chief Scientific Officer | $1.7M 20,536 shares | -25% | |
| 38Weak | IONIS PHARMACEUTICALS INC | Allene M. Diaz director | $864k 10,111 shares | -73% | |
| 15Weak | IONIS PHARMACEUTICALS INC | Holly B. Kordasiewicz EVP, Chief Development Officer | $31k 362 shares | -2% | |
| 39Weak | IONIS PHARMACEUTICALS INC | Joseph Klein III director | $910k 11,518 shares | -51% | |
| 32Weak | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $452k 5,635 shares | -55% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Eugene Schneider EVP, Chf Clinical Develop Ofcr | $2.1M 26,000 shares | -25% | |
| 23Weak | IONIS PHARMACEUTICALS INC | Patrick R. O'Neil EVP CLO & General Counsel | $246k 3,069 shares | -5% | |
| 43Moderate | IONIS PHARMACEUTICALS INC | Eric Swayze EVP Research | $839k 10,602 shares | -33% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Brett P Monia Chief Executive Officer | $6.8M 85,637 shares | -33% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.